IP Library › Granted Patent US 11,505,620

Granted Patent B2

US 11,505,620 · App. 16/411,242 · Granted Nov 22, 2022

Methods of detecting plasma kallikrein

Inventors: Daniel J. Sexton (Melrose, MA); Malini Viswanathan (Burlington, MA)

Assignee: Takeda Pharmaceutical Company Limited

C07K16/40 A61K49/0004 A61K2039/505 C07K2317/76 C07K2317/92

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 11,505,620
App. No.: 16/411,242
Granted: Nov 22, 2022
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Plasma kallikrein binding proteins and methods of using such proteins are described.

Claims (100)

1. A method of detecting plasma kallikrein in a subject, the method comprising

administering an anti-plasma kallikrein (pKal) antibody to a subject; and

detecting an interaction between the antibody and plasma kallikrein in the subject, wherein the antibody comprises:

(i) a heavy chain immunoglobulin variable domain sequence comprising a complementarity determining region 1 (CDR1) sequence set forth in SEQ ID NO: 141, a complementarity determining region 2 (CDR2) sequence set forth in SEQ ID NO: 177, and a complementarity determining region 3 (CDR3) sequence set forth in SEQ ID NO: 213, and a light chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 33, a CDR2 sequence set forth in SEQ ID NO: 69, and a CDR3 sequence set forth in SEQ ID NO: 105;

(ii) a heavy chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 139, a CDR2 sequence set forth in SEQ ID NO: 175, and a CDR3 sequence set forth in SEQ ID NO: 211, and a light chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 31, a CDR2 sequence set forth in SEQ ID NO: 67, and a CDR3 sequence set forth in SEQ ID NO: 103;

(iii) a heavy chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 134, a CDR2 sequence set forth in SEQ ID NO: 170, and a CDR3 sequence set forth in SEQ ID NO: 206, and a light chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 26, a CDR2 sequence set forth in SEQ ID NO: 62, and a CDR3 sequence set forth in SEQ ID NO: 98;

(iv) a heavy chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 1111, a CDR2 sequence set forth in SEQ ID NO: 1112, and a CDR3 sequence set forth in SEQ ID NO: 1113, and a light chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 1097, a CDR2 sequence set forth in SEQ ID NO: 1103, and a CDR3 sequence set forth in SEQ ID NO: 1109;

(v) a heavy chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 1893, a CDR2 sequence set forth in SEQ ID NO: 1907, and a CDR3 sequence set forth in SEQ ID NO: 1921, and a light chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 1851, a CDR2 sequence set forth in SEQ ID NO: 1865, and a CDR3 sequence set forth in SEQ ID NO: 1879;

(vi) a heavy chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 151, a CDR2 sequence set forth in SEQ ID NO: 187, and a CDR3 sequence set forth in SEQ ID NO: 223, and a light chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 43, a CDR2 sequence set forth in SEQ ID NO: 79, and a CDR3 sequence set forth in SEQ ID NO: 115;

(vii) a heavy chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 145, a CDR2 sequence set forth in SEQ ID NO: 181, and a CDR3 sequence set forth in SEQ ID NO: 217, and a light chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 37, a CDR2 sequence set forth in SEQ ID NO: 73, and a CDR3 sequence set forth in SEQ ID NO: 109;

(viii) a heavy chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 149, a CDR2 sequence set forth in SEQ ID NO: 185, and a CDR3 sequence set forth in SEQ ID NO: 221, and a light chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 41, a CDR2 sequence set forth in SEQ ID NO: 77, and a CDR3 sequence set forth in SEQ ID NO: 113;

(ix) a heavy chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 1894, a CDR2 sequence set forth in SEQ ID NO: 1908, and a CDR3 sequence set forth in SEQ ID NO: 1922, and a light chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 1852, a CDR2 sequence set forth in SEQ ID NO: 1866, and a CDR3 sequence set forth in SEQ ID NO: 1880;

(x) a heavy chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 1895, a CDR2 sequence set forth in SEQ ID NO: 1909, and a CDR3 sequence set forth in SEQ ID NO: 1923, and a light chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 1853, a CDR2 sequence set forth in SEQ ID NO: 1867, and a CDR3 sequence set forth in SEQ ID NO: 1881;

(xi) a heavy chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 1896, a CDR2 sequence set forth in SEQ ID NO: 1910, and a CDR3 sequence set forth in SEQ ID NO: 1924, and a light chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 1854, a CDR2 sequence set forth in SEQ ID NO: 1868, and a CDR3 sequence set forth in SEQ ID NO: 1882;

(xii) a heavy chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 1897, a CDR2 sequence set forth in SEQ ID NO: 1911, and a CDR3 sequence set forth in SEQ ID NO: 1925, and a light chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 1855, a CDR2 sequence set forth in SEQ ID NO: 1869, and a CDR3 sequence set forth in SEQ ID NO: 1883;

(xiii) a heavy chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 1899, a CDR2 sequence set forth in SEQ ID NO: 1913, and a CDR3 sequence set forth in SEQ ID NO: 1927, and a light chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 1857, a CDR2 sequence set forth in SEQ ID NO: 1871, and a CDR3 sequence set forth in SEQ ID NO: 1885;

(xiv) a heavy chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 1900, a CDR2 sequence set forth in SEQ ID NO: 1914, and a CDR3 sequence set forth in SEQ ID NO: 1928, and a light chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 1858, a CDR2 sequence set forth in SEQ ID NO: 1872, and a CDR3 sequence set forth in SEQ ID NO: 1886;

(xv) a heavy chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 1902, a CDR2 sequence set forth in SEQ ID NO: 1916, and a CDR3 sequence set forth in SEQ ID NO: 1930, and a light chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 1860, a CDR2 sequence set forth in SEQ ID NO: 1874, and a CDR3 sequence set forth in SEQ ID NO: 1888;

(xvi) a heavy chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 125, a CDR2 sequence set forth in SEQ ID NO: 161, and a CDR3 sequence set forth in SEQ ID NO: 197, and a light chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 17, a CDR2 sequence set forth in SEQ ID NO: 53, and a CDR3 sequence set forth in SEQ ID NO: 89;

(xvii) a heavy chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 136, a CDR2 sequence set forth in SEQ ID NO: 172, and a CDR3 sequence set forth in SEQ ID NO: 208, and a light chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 28, a CDR2 sequence set forth in SEQ ID NO: 64, and a CDR3 sequence set forth in SEQ ID NO: 100;

(xviii) a heavy chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 116, a CDR2 sequence set forth in SEQ ID NO: 152, and a CDR3 sequence set forth in SEQ ID NO: 188, and a light chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 8, a CDR2 sequence set forth in SEQ ID NO: 44, and a CDR3 sequence set forth in SEQ ID NO: 80; or

(xix) a heavy chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 127, a CDR2 sequence set forth in SEQ ID NO: 163, and a CDR3 sequence set forth in SEQ ID NO: 199, and a light chain immunoglobulin variable domain sequence comprising a CDR1 sequence set forth in SEQ ID NO: 19, a CDR2 sequence set forth in SEQ ID NO: 55, and a CDR3 sequence set forth in SEQ ID NO: 91.

2. The method of claim 1 , wherein the antibody comprises:

(i) a heavy chain variable domain sequence set forth in SEQ ID NO: 275 and a light chain variable domain sequence set forth in SEQ ID NO: 274;

(ii) a heavy chain variable domain sequence set forth in SEQ ID NO: 271 and a light chain variable domain sequence set forth in SEQ ID NO: 270;

(iii) a heavy chain variable domain sequence set forth in SEQ ID NO: 261 and a light chain variable domain sequence set forth in SEQ ID NO: 260;

(iv) a heavy chain variable domain sequence set forth in SEQ ID NO: 1119 and a light chain variable domain sequence set forth in SEQ ID NO: 1118;

(v) a heavy chain variable domain sequence set forth in SEQ ID NO: 1952 and a light chain variable domain sequence set forth in SEQ ID NO: 1938;

(vi) a heavy chain variable domain sequence set forth in SEQ ID NO: 1997 and a light chain variable domain sequence set forth in SEQ ID NO: 1994;

(vii) a heavy chain variable domain sequence set forth in SEQ ID NO: 283 and a light chain variable domain sequence set forth in SEQ ID NO: 282;

(viii) a heavy chain variable domain sequence set forth in SEQ ID NO: 291 and a light chain variable domain sequence set forth in SEQ ID NO: 290;

(ix) a heavy chain variable domain sequence set forth in SEQ ID NO: 1954 and a light chain variable domain sequence set forth in SEQ ID NO: 1940;

(x) a heavy chain variable domain sequence set forth in SEQ ID NO: 1956 and a light chain variable domain sequence set forth in SEQ ID NO: 1942;

(xi) a heavy chain variable domain sequence set forth in SEQ ID NO: 1957 and a light chain variable domain sequence set forth in SEQ ID NO: 1943;

(xii) a heavy chain variable domain sequence set forth in SEQ ID NO: 1960 and a light chain variable domain sequence set forth in SEQ ID NO: 1946;

(xiii) a heavy chain variable domain sequence set forth in SEQ ID NO: 1953 and a light chain variable domain sequence set forth in SEQ ID NO: 1939;

(xiv) a heavy chain variable domain sequence set forth in SEQ ID NO: 1955 and a light chain variable domain sequence set forth in SEQ ID NO: 1941;

(xv) a heavy chain variable domain sequence set forth in SEQ ID NO: 1959 and a light chain variable domain sequence set forth in SEQ ID NO: 1945;

(xvi) a heavy chain variable domain sequence set forth in SEQ ID NO: 243 and a light chain variable domain sequence set forth in SEQ ID NO: 242;

(xvii) a heavy chain variable domain sequence set forth in SEQ ID NO: 265 and a light chain variable domain sequence set forth in SEQ ID NO: 264;

(xviii) a heavy chain variable domain sequence set forth in SEQ ID NO: 225 and a light chain variable domain sequence set forth in SEQ ID NO: 224; or

(xix) a heavy chain variable domain sequence set forth in SEQ ID NO: 247 and a light chain variable domain sequence set forth in SEQ ID NO: 246.

3. The method of claim 1 , wherein the antibody has an apparent inhibition constant (Ki,app) of plasma kallikrein of less than 100 nM.

4. The method of claim 3 , wherein the antibody has an apparent inhibition constant (Ki,app) of plasma kallikrein of less than 10 nM.

5. The method of claim 4 , wherein the antibody has an apparent inhibition constant (Ki,app) of plasma kallikrein of less than 1 nM.

6. The method of claim 1 , wherein the antibody is a full length antibody or an antigen-binding fragment thereof.

7. The method of claim 6 , wherein the antibody is an IgG or a soluble Fab (sFab).

8. The method of claim 1 , wherein the antibody comprises a detectable label.

9. The method of claim 8 , wherein the detectable label is a radionuclide or an MRI-detectable label.

10. The method of claim 1 , wherein detecting the interaction comprises imaging the subject.

11. The method of claim 1 , wherein the subject has or is suspected of having a plasma kallikrein associated disorder.

12. The method of claim 11 , wherein the plasma kallikrein associated disorder is selected from the group consisting of rheumatoid arthritis, gout, intestinal bowel disease, oral mucositis, neuropathic pain, inflammatory pain, spinal stenosis-degenerative spine disease, arterial or venous thrombosis, post operative ileus, aortic aneurysm, osteoarthritis, vasculitis, edema, hereditary angioedema, cerebral edema, pulmonary embolism, stroke, clotting induced by ventricular assistance devices or stents, head trauma or peri-tumor brain edema, sepsis, acute middle cerebral artery, ischemic event, restenosis, systemic lupus erythematosis nephritis/vasculitis, and burn injury.

13. A method of detecting plasma kallikrein in a sample, the method comprising

contacting the sample with an anti-plasma kallikrein (pKal) antibody; and

detecting an interaction between the antibody and plasma kallikrein in the sample, if present; wherein the antibody comprises:

14. The method of claim 13 , wherein the sample is a sample obtained from a subject.

15. The method of claim 14 , wherein the sample is a biopsy sample.

16. The method of claim 13 , wherein the antibody comprises: